Altis Labs

We’re excited to share that we have entered into a collaboration agreement with @JNJInnovMed. Trained on the industry’s most comprehensive multimodal real-world dataset, our AI models will support the evaluation of novel outcome measures that have the potential to accelerate trial timelines, reduce costs, and improve evidence generation in drug development. This collaboration reflects our commitment to accelerating clinical development with state-of-the-art AI.

At the Canadian Breast Cancer Symposium, we presented a first glimpse of IPRO’s ability to generalize across cancer types. In this study, our AI model analyzed pretreatment breast cancer scans having trained solely on lung cancer data. Remarkably, IPRO stratified survival outcomes more effectively than traditional measures like TNM stage and patient age in this population. These early results are a promising signal as we continue expanding our work across indications. Thanks to Dr. Omar Khan and our co-authors from @UCalgary and @HamHealthSci for their collaboration on this work. #breastcancer #ai #clinicaltrial Link to poster: eps102.eposterscholar.com/epo/posters/21

We're proud to share that results from @AstraZeneca's evaluation of our AI-powered External Control Arm were presented at #ISPOR2025 today. AZ's analysis showed that our ECA replicated survival outcomes of the control arm and preserved the observed treatment effect.

Thank you @brittanytrang for featuring the recent results from @AstraZeneca's evaluation of our AI models. We have a lot more work to do, but we're excited to begin to showcase how AI can accelerate clinical development with a stronger predictor of overall survival, the gold standard measure of efficacy in oncology trials.

"There is risk in not acting". Engaging discussions on #AI and #HealthData at #CTOConf2024! This morning’s panel is diving into how data-driven tools are reshaping #clinicaltrials for better precision and outcomes.

The @altislabs team is excited to announce that two abstracts have been accepted at @myESMO for poster presentation this year, illustrating our latest research with biopharma partners and research collaborators. Please reach out if you're headed to Barcelona for #ESMO24 this September, we would love to connect!

Excited to be back in NYC next week for the AI x Bio Summit!

Join me on Wednesday for a discussion about Digital Twins in oncology trials here in Toronto at #MaRSImpactHealth, Canada's largest healthcare conference. The panel will include our partners at @BayerPharma and will be moderated by science journalist @AyeshaR1202. When: Wednesday, 2:20pm ET Where: @MaRSDD, Toronto Register here: impacthealth.marsdd.com

Find out how Toronto-based @altislabs is transforming the future of clinical trials and healthcare with AI. statnews.com/2024/04/03/ai-…

Biopharma companies are beginning to turn to AI to enroll people in clinical trials. trib.al/0R11vzW

Excellent overview by @ADeAngelis_bio on how AI is transforming clinical trials. Our CEO @FelixBL92 explains how we help sponsors like @AstraZeneca @BayerPharma run smaller, faster and more successful trials so that patients get access to most effective novel treatments sooner

Fantastic article by @ADeAngelis_bio on how our team at @altislabs is using AI to transform clinical trials – thank you for the shoutout! If sponsors focus too heavily on reductionist tumor size measurements to guesstimate efficacy, “they might be pushing a drug into late-stage development that’s not going to improve survival, or deprioritize a drug that would have been a blockbuster and would have significantly improved outcomes.”

"The goal of what they call 'common-sense oncology' is to prioritize treatments that meaningfully improve survival and quality of life." Such an important initiative led by Drs. @oncology_bg, @chrisbooth, Chris Booth, and @EAEisenhauer.

Had the design of some of these trials not formally tested overall survival, the overall risk–benefit assessment might not have been considered favourable."

...The difference in median PFS between the experimental and control groups ranged from –1.7 months (favouring the control group) to 4.3 months, whereas the difference in median OS ranged from 1.2 months to 15.8 months...

Important analysis published by FDA evaluating the utility of PFS and ORR.

Delighted to present at the @NHS's Integrated Care Systems Congress, where we gave an overview of how we enable more efficient drug development using our computational imaging #AI models. Thank you to @GIANT_health for the invitation!

Congratulations to the @uk_biobank and all participating volunteers on this fantastic milestone! A massive contribution to health research.

Congratulations to our partners @AstraZeneca and @BayerPharma for making the top 10 in @CBInsights Pharma AI Readiness Index! cbinsights.com/research/ai-re…